Arrien Pharmaceuticals, LLC. logo

Arrien Pharmaceuticals, LLC.

Arrien Pharmaceuticals is a small molecule targeted therapeutics drug discovery and development company targeting kinase signaling and nuclear receptor pathways for treating Inflammation, Autoimmune, Cancer, and Neurodegenerative diseases.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.arrienpharma.com
Founded2011
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
9980 South, 300 West, Suite # 200,UT 84070
Salt Lake City
United States
Email
Contact Number
+1 801-349-5355

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/arrien-pharmaceuticals” connections=”true” suffix=””]

Arriens proprietary Fragment-Field Design (FFD) Technology_ involves the identification of targets specific fragments or small chemical scaffolds that exhibit weaker binding affinity (typically 100-1 ?M) and are capable of becoming lead candidates. Other platforms includes: Scaffold-Based Drug Discovery (an in-house scaffold-library size between >150-<350 MW to facilitate the identification of novel scaffolds) and Structure-Based Design strategies (prediction of binding affinities and binding modes of each compound by means of Virtual Ligand Screening method).

In 2017, Arrien Pharmaceuticals has granted Worldwide exclusive license of ARN-6039 to Boston Pharmaceuticals.